Jiuzhitang Maker Cell Technology

Focus: Jiuzhitang Maker Cell Technology is a China-based biotechnology company specializing in stem cell technologies and cell therapy development. The company operates in the emerging cell therapy segment with limited public visibility on scale and market position.

Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Jiuzhitang Maker Cell Technology

AI assessmentNot Hiring

No open roles listed right now. Follow Jiuzhitang Maker Cell Technology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

hBMMSC

Autism Spectrum Disorder

Phase 1

Clinical Trials (1)

NCT07177677A Study of Mesenchymal Stem Cell in the Treatment of Autism Spectrum Disorder

Phase 1

Help build intelligence for Jiuzhitang Maker Cell Technology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build early-stage cell therapy programs at the frontier of regenerative medicine in a high-growth biotech market.
Access to China's expanding biotech ecosystem and potential first-mover advantage in emerging cell therapy indications.
Ground-floor career positioning if the company successfully advances stem cell programs through clinical development.

Watch Out For

Zero active clinical trials reported and no disclosed pipeline programs suggest early preclinical stage with uncertain timelines to clinical data.
No current open job positions and lack of transparency on funding, employee count, and financial stability create visibility gaps for career planning.
Limited public publications and patent disclosures indicate low R&D output or communication relative to peer companies in cell therapy.

Generated by Claude from Jiuzhitang Maker Cell Technology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

it-hMSC

Ischemic Stroke

Phase 1/2

Clinical Trials (1)

NCT04590118Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)

Phase 1/2

human Bone Marrow Mesenchymal Stem Cell

Autoimmune Pulmonary Alveolar Proteinosis

Phase 2

Clinical Trials (1)

NCT06111846Study of Human Bone Marrow Mesenchymal Stem Cells in APAP

Phase 2